Seminar Series

Expanding the actionable genome

A physician-scientist working at the intersection of clinical oncology and genomics, David Solit, MD has helped shape how molecular data are used to guide cancer therapy. His clinical work focuses on prostate and bladder cancers, while his laboratory research has advanced understanding of MAP kinase pathway inhibition and mechanisms of resistance to RAF and MEK inhibitors. 

Solit's team was among the first to apply whole genome sequencing approaches to uncover previously unrecognized predictors of drug response—work that informed the NCI Extraordinary Responder Initiative. As Co-Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, he leads efforts to integrate genomic and clinical data at scale. Through initiatives such as the MSK-IMPACT assay, Solit's lab has prospectively sequenced more than 150,000 tumors, creating one of the most comprehensive molecular datasets in oncology.

This seminar will examine how large-scale tumor profiling and integrated data systems inform therapeutic development, refine patient stratification, and shape clinical decision-making. For investigators and trainees, the session offers a clear view of how genomic insights move from discovery to implementation—and where key challenges in interpretation, resistance, and trial design remain. 

Sponsored by Case CCC and the Molecular Oncology Program